STSergei A. Tjulandin

Sergei A. Tjulandin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sergei A. Tjulandin has a total of 504 co-authors. Here are the top co-authors by number of shared publications:

  • Mikhail Yu. Fedyanin

    Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center

    35 shared publications
  • Alexey A. Tryakin

    N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

    34 shared publications
  • М. Ю. Федянин

    ФГБУ «Научный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России; ГБУЗ «Московский многопрофильный клинический центр «Коммунарка» Департамента здравоохранения г. Москвы»; ФГБУ «Национальный медико-хирургический центр им. Н. И. Пирогова» Минздрава России

    14 shared publications
  • Ilya A. Pokataev

    Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health

    13 shared publications
  • Alexey A. Rumyantsev

    N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

    8 shared publications
  • D. A. Chekini

    Blokhin National Medical Research Center of Oncology

    6 shared publications

Latest Publications

  • Open Access

    Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population

    by A. A. Rumyantsev, I. A. Pokataev, T. E. Tikhomirova, A. S. Shevchuk, A. Yu. Anokhin, S. L. Gutorov, E. V. Glazkova, S. A. Tjulandin, I. S. Stilidi, А. А. Румянцев, et al.

    Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.

  • Platinum-based and non-platinum-based chemotherapy in early recurrence of ovarian cancer: retrospective study

    by А. А. Rumyantsev, Т. Е. Тikhomirova, I. А. Pokataev, А. S. Shevchuk, S. А. Tyulyandin

    Background. Platinum-based chemotherapy may be active in relapsed ovarian cancer (OC) regardless of the platinum-free interval (PFI). Aim. To clarify the role of platinum agents in the treatment of platinum-resistant recurrences of OC. Materials and methods. Patients with recurrent serous or endometrioid high-grade OC with PFI of ≤ 6 months treated between 2014 and 2024 were included in the study. Patients could receive standard non-platinum-based or platinum-based chemotherapy for the first or second recurrence of OC, with or without bevacizumab. Patients were excluded if they were platinum-refractory, had previously received more than 2 lines of systemic chemotherapy or had maintenance therapy with poly(ADP-ribose) polymerases inhibitors. The primary endpoint of the study was progression-free survival (PFS). The statistical hypothesis assumed the inclusion of ≥ 350 patients to identify clinically relevant differences (reduction in hazard ratio (HR) of ≥ 30 %) in PFS between study arms, with an expected median PFS in the control group equal to 4 months (with p = 0.05 and p = 0.2). Results. A total of 354 patients were included, significant imbalances were noted between arms in the frequency of pathogenic BRCA1/2 mutations (p = 0.039), duration of PFI (p 0.001), and administered non-platinum agents. Median PFS was 7.4 months and 3.2 months in platinum-based and non-platinum-based chemotherapy arms, respectively (HR 0.44; p 0.001), and median overall survival was 23.0 months and 16.5 months (HR 0.73; p = 0.011). Multivariate analysis confirmed independent effect of platinum-based chemotherapy on PFS (HR 0.57; p 0.001). Conclusion. The results of this study suggest superior efficacy of platinum-based chemotherapy in the treatment of early recurrences of OC. Prospective studies are needed to confirm these findings.

  • Open Access

    Antitumor mechanisms of acetylsalicylic acid: a review of current evidence

    by O. A. Kuznetsova, M. S. Manukyan, A. A. Lebedeva, A. A. Tryakin, M. Yu. Fedyanin, M. M. Bratukhina, S. A. Tjulandin

    Acetylsalicylic acid, more commonly known as aspirin, has been used in clinical practice for decades as analgesic, antipyretic and anti-inflammatory drug. In recent years, its potential in prevention and therapy of oncological diseases has become a new topic of research. The article summarizes modern data on molecular and cellular mechanisms underlying antitumor action of aspirin. The main targets of acetylsalicylic acid are cyclooxigenase-1 and cyclooxigenase-2, inhibition of which leads to a decrease in prostaglandin production and modulation of inflammatory response. Additionally, aspirin affects apoptosis, proliferation, angiogenesis, and metastasis of tumor cells. Cyclooxigenases-independent mechanisms are also considered including activation of AMP-dependent protein kinase (AMPK), inhibition of nuclear transcription factor κB (NF-κB) and RhoA/ROCK pathway; results of clinical trials investigating efficacy of aspirin in various malignant neoplasms including colorectal, breast and prostate cancers are presented. The review focuses on the necessity of further studies aimed at identification of predictive biomarkers and stratification of patients who can have the strongest response to therapy taking into account molecular and genetic profile of the tumors (for example, hyperexpression of cyclooxygenase-2 or alterations in the PI3K/AKT signaling pathway).

  • Open Access

    Russian consensus on prevention, diagnosis and treatment of gastric cancer. Systemic therapy issues

    by E. V. Artamonova, N. S. Besova, L. V. Bolotina, L. Yu. Vladimirova, L. G. Zhukova, E. O. Ignatova, V. M. Moiseenko, I. A. Pokataev, N. E. Semenov, D. L. Stroyakovskii, et al.

    The Russian consensus on prevention, diagnostic and treatment of gastric cancer was prepared on the initiative of the Moscow clinical scientific center named after A. S. Loginov on the Delphi method. Its aim was to clarify and consolidate the opinions of specialists on the most relevant issues of prevention, diagnosis and treatment of gastric cancer. An interdisciplinary approach was provided by the participation of leading gastroenterologists, oncologists and surgeons.


  • Efbemalenograstim Alfa, a Long-Acting Granulocyte Colony-Stimulating Factor Fusion Protein Without PEGylation, Versus Pegfilgrastim for Management of Chemotherapy-Induced Neutropenia in Patients With Breast Cancer: Results of a Phase III Randomized Noninferiority Trial

    by John A. Glaspy, Igor Bondarenko, Sergei Tjulandin, Michael Auerbach

    PURPOSE: This phase III noninferiority (NI) trial evaluated the efficacy and safety of efbemalenograstim alfa, a novel non-PEGylated, long-acting, human granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia (CIN), in patients with breast cancer. MATERIALS AND METHODS: Adult patients with stage I-III invasive breast cancer (n = 393) undergoing docetaxel and cyclophosphamide chemotherapy treatment were randomly assigned (1:1) to receive a single fixed dose of efbemalenograstim alfa or pegfilgrastim 24 hours after each chemotherapy administration. The primary objective was to demonstrate NI or potential superiority of efbemalenograstim alfa compared with pegfilgrastim. The primary end point is the duration of severe neutropenia (DSN) in cycle 1 with a NI margin of 0.6 days. Additional end points included incidence of severe neutropenia (ISN), febrile neutropenia, infections, and incidence of treatment-emergent adverse events (TEAEs). RESULTS: Among patients randomly assigned to efbemalenograstim alfa (n = 197), the mean DSN in cycle one was 0.2 ± 0.51 days, compared with 0.2 ± 0.45 days for the pegfilgrastim group (n = 196), with a CI of –0.1 to 0.1 days ( P = .7) for the treatment comparison, confirming NI. There was a lower ISN in those receiving efbemalenograstim alfa at cycle 4 ( P = .050). Lower ISN in later cycles was observed in all three efbemalenograstim alfa phase III trials. Treatment with efbemalenograstim alfa was safe, with low incidences of serious AEs and TEAEs, and an overall safety profile comparable with the pegfilgrastim group. Similar to ISN, fewer grade 4 neutropenias in the efbemalenograstim alfa group were observed compared with pegfilgrastim. CONCLUSION: Results demonstrated that efbemalenograstim alfa was noninferior to current CIN therapy (pegfilgrastim) with comparable efficacy and safety profiles in cycle 1 and showed evidence of less neutropenia in later cycles.


  • Open Access

    TIP regimen (paclitaxel, ifosfamide, cisplatin) in nonseminomatous germ cell tumors with poor-prognosis and unfavorable decline of serum tumor markers: final results

    by E. R. Israelyan, A. A. Tryakin, A. A. Rumyantsev, M. Yu. Fedyanin, P. V. Kononets, S. S. Gerasimov, V. B. Matveev, M. I. Volkova, A. V. Klimov, A. I. Semenova, et al.

    Background: Patients with germ cell tumors (GCTs) and poor-prognosis demonstrate unsatisfactory oncological outcomes, with a one-year progression-free survival (PFS) rate of approximately 50 %. We hypothesized that switching the chemotherapy regimen to TIP (paclitaxel, ifosfamide (mesna), cisplatin) in cases of unfavorable decline of serum tumor markers (STMs) after the first cycle of BEP (bleomycin, etoposide, cisplatin) could improve treatment outcomes in this subgroup of patients.Materials and methods: A multicenter, prospective, non-randomized phase II study included patients with nonseminomatous GCTs and poor-prognosis according to IGCCCG. All patients received the first cycle of chemotherapy in BEP regimen. Patients with an unfavorable decline of STMs subsequently received 4 cycles of TIP regimen (paclitaxel 120 mg / m² on days 1 and 2 + ifosfamide 1500 mg / m² on days 2–5 (+ mesna) + cisplatin 25 mg / m² on days 2–5 + G-CSF). In the presence of residual tumors larger than 1 cm and the technical feasibility of removal, surgical treatment was performed. The primary endpoint was one-year PFS.Results: From 2017 to 2023, 34 patients were included in the study. Enrollment was prematurely closed due to an extremely low likelihood of achieving the primary endpoint. One-year PFS and overall survival (OS) were 57.1 % and 74.4 %, respectively. The favorable response rate (complete response + partial response with normalization STM) was observed in 55,8 % of patients. Disease progression was observed in 21 patients, with the central nervous system being the first site of progression in 8 (37 %) of them. Surgical treatment was performed in 16 patients, with viable tumor obtained in 4 patients. Conducting the first cycle in a “stabilization» mode for ultra-high-risk patients did not affect PFS (p = 0.28) or OS (p = 0.434). The toxicity profile of the TIP regimen was acceptable.Conclusion: Switching from BEP to TIP for patients with nonseminomatous GCTs and an unfavorable decline of STMs did not demonstrate efficacy. Further exploration of alternative therapeutic approaches is needed to improve treatment outcomes.

  • Open Access

    Impact of PARP inhibitor maintenance therapy after initial treatment on the efficacy of subsequent therapy in ovarian cancer: a propensity score matching analysis

    by А. А. Rumyantsev, Т. Е. Tihomirova, А. S. Tsareva, S. L. Gutorov, А. N. Lud, А. P. Chernova, S. A. Tjulandin

    Introduction: progression of advanced epithelial ovarian cancer (EOC) on olaparib may diminish the efficacy of subsequent chemotherapy in recurrent disease setting. However, the impact of progression of EOC during maintenance therapy with olaparib after frontline therapy has not been well studied.Materials and methods: this retrospective study enrolled patients of BRCA / HRD + FIGO stage III–IV EOC with confirmed progressive disease after frontline treatment treated since 2014 until 2022 who either received (arm A) or not (arm B) olaparib as maintenance therapy. To ensure the balance of the compared groups during the study propensity score matching analysis was conducted (cardinality method using MatchIT package in R) with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, the duration of platinum-free interval after the frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was progression-free survival (PFS).Results: the initial population consisted of 259 patients, after the matching procedure 76 patients were enrolled in the study. The median age of patients was 48 years in the arm A and 50 years in the arm B (p = 0.989), 12 (32 %) had FIGO stage IV in both arms (p = 1.000), 25 (66 %) patients in both arms had platinum-free interval ≥ 12 months. With a median follow-up of 42.8 mo. (0.6–70.1 months) median PFS was 6.9 (95 % CI 6.2–10.6 months) and 12.2 (95 % CI 9. 6–21.3 months) in arm A and B, respectively (hazard ratio [HR] 2.89; 95 % CI 1.63–5.12; p < 0.001). Median overall survival was 23.2 months. and 68.2 mo., respectively (HR 4.15; 95 % CI 1.62–10.6).Conclusion: efficacy of subsequent chemotherapy is apparently reduced following progression of BRCA / HRD + EOC on maintenance olaparib therapy in frontline setting. Further trials should assess optimal approaches for these patients.


  • Open Access

    What we know about the new coronavirus infection in cancer patients

    by P. S. Feoktistova, E. A. Azarova, D. M. Volkova, A. A. Emelyanova, A. K. Iglamov, A. N. Igumnova, A. Z. Isyangulova, M. S. Mazhbich, K. V. Menshikov, Yu. I. Murzina, et al.

    The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.


  • Open Access

    Mutations in Mismatch Repair Genes and Microsatellite Instability Status in Pancreatic Cancer

    by Marina Emelyanova, Anna Ikonnikova, Alexander Pushkov, Elena Pudova, George Krasnov, Anna Popova, Ilya Zhanin, Darya Khomich, Ivan Abramov, Sergei Tjulandin, et al.

    Patients with pancreatic cancer (PC) showing mismatch repair (MMR) deficiency may benefit from immunotherapy. Microsatellite instability (MSI) is a hallmark of MMR deficiency (MMR-D). Here, we estimated the prevalence of MSI in PC, investigated germline and somatic mutations in the three MMR genes (MLH1, MSH2, and MSH6), and assessed the relationship between MMR genes mutations and MSI status in PC. Clinical specimens from PC patients were analyzed using targeted next-generation sequencing, including paired normal and tumor specimens from 155 patients, tumor-only specimens from 86 patients, and normal-only specimens from 379 patients. The MSI status of 235 PCs was assessed via PCR. Pathogenic/likely pathogenic (P/LP) germline variants in the MMR genes were identified in 1.1% of patients, while somatic variants were found in 2.6% of patients. No MSI-H tumors were detected. One patient carried two variants (P (VAF = 0.57) and LP (VAF = 0.25)) simultaneously; however, their germline/somatic status remains unknown due to the investigation focusing solely on the tumor and MSI analysis was not performed for this patient. MSI is rare in PC, even in tumors with MMR genes mutations. Our findings underscore the importance of assessing tumor MMR-D status in PC patients with confirmed Lynch syndrome when deciding whether to prescribe immunotherapy.